Compare AGRZ & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGRZ | SILO |
|---|---|---|
| Founded | 2020 | 2010 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Apparel |
| Sector | Consumer Staples | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.1M |
| IPO Year | 2024 | 2011 |
| Metric | AGRZ | SILO |
|---|---|---|
| Price | $2.93 | $1.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 198.1K | 33.5K |
| Earning Date | 11-03-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.98 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $72,102.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $1.10 |
| 52 Week High | $5.34 | $10.43 |
| Indicator | AGRZ | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 57.34 | 22.31 |
| Support Level | $2.71 | $1.10 |
| Resistance Level | $3.78 | $4.80 |
| Average True Range (ATR) | 0.58 | 0.10 |
| MACD | -0.16 | 0.03 |
| Stochastic Oscillator | 7.70 | 17.07 |
Agroz Inc is a vertically integrated agricultural technology (AgTech) company focused on designing, innovating, developing, building, operating and managing large, commercial-scale, industrial-grade indoor CEA vertical farms using CEA practices. Its mission is to improve food safety, food security, and sustainability for society by creating a reliable, accessible food supply through its AgTech products and services. CEA vertical farming is an agricultural method involving crop cultivation through vertically stacked layers in a controlled indoor environment. CEA practices are defined by growing produce in spaces where environmental conditions can be controlled and manipulated to match the needs of specific plants.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.